Citi yesterday morning initiated coverage of Agios Pharmaceuticals (AGIO) with a Buy rating and $38 price target Citi also opened a “positive 30-Day catalyst watch” on Agios into the December 7 FDA action date for Pyrukynd in thalassemia. It believes the Phase 3 data support approval and thinks the recent selloff in the shares on the sickle cell disease data is overdone.
TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on AGIO:
- Agios Pharmaceuticals initiated with a Buy at Truist
- Agios Pharmaceuticals price target lowered to $20 from $37 at JPMorgan
- Agios Pharmaceuticals price target lowered to $25 from $40 at Goldman Sachs
- Leerink upgrades Agios to Outperform after 51% pullback
- Agios Pharmaceuticals upgraded to Outperform from Market Perform at Leerink